Prognostic significance of the immunohistochemical localization and serological detection of CA19-9 tumor antigen in colon carcinoma

Journal of B.U.ON.

Volumn 9, Issue 1, 2004, Pages 73-76

  Frangos Plemenos, M ^a   Dimas, C ^a   Kotsios, A ^a   Gennatas, K ^a   Kondi Pafiti, Agatha ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

CA19 9 serum tumor marker; CA19 9 tumor antigen; Colon cancer; Immunohistochemistry

Indexed keywords

CA 19-9 ANTIGEN; TUMOR MARKER;

ANTIGENICITY; ARTICLE; CANCER GRADING; CELL MEMBRANE; COLON CANCER; COLON CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; SEROLOGY; TUMOR DIFFERENTIATION;

EID: 2442719080     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Magnani JL, Brockhaus M, Smith DF et al. A monosialoganglioside is a monoclonal antibody-defined antigen of colon carcinoma. Science 1981; 212: 55-56.
2. Magnani JL, Nilsson B, Brockhans M et al. A monoclonal antibody defined associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentose II. J Biol Chem 1982; 257: 14365-14369.
3. Magnani JL, Steplewski Z, Kortowski H et al. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody CA19-9 in the sera of patients as mucin. Cancer Res 1983; 43: 5489-5492.
4. Marc DR, Chenp PW, Perini F. Altered expression of sialylated carbohydrate antigens in colonic carcinoma cells. Glycoconj J 1998; 15: 1155-1163.
5. Rhodes TM. Usefulness of novel tumor markers. Ann Oncol 1999; 10 (Suppl 4): 118-121.
6. Paraskeva C, Corfield AP, Harper S et al. Colorectal carcinogenesis: sequential steps in the in vitro immortalization and transformation of human colonic epithelial cells Anticancer Res 1990; 10: 1189-1200.
7. Nakaga T, Sawai T, Tsuji T et al. Circulating sialyl Lewis(x), sialyl Lewis(a) and sialyl Tn antigens in colorectal cancer patients: multivariate analysis of predictive factors for serum antigen levels. J Gastroenterol 2001; 36: 166-172.
8. Narimatsu H, Iwasaki H, Nishihara S et al. Genetic evidence for the Lewis enzyme which synthesizes type I Lewis antigens in colon tissue and intracellular localization of the enzyme. Cancer Res 1996; 56: 330-338.
9. Del Villano BC, Zurawinski VR. The carbohydrate antigenic determinant 19.9. A monoclonal antibody defined tumor marker. In: Aloisi RM, Hyxn J (eds). Immunodiagnostics. New York, AR Liss Inc, 1983, pp, 269-282.
10. Lamerz R. Role of tumor markers, cytogenetics. Ann Oncol 1999; 10 (Suppl 4): 145-149.
11. Thomas WM, Robertson JF, Price MR et al. Failure of CA19-9 to detect asymptomatic colorectal carcinoma. Br J Cancer 1991; 63: 975-976.
12. Webb A, Scottt-Mackie P, Cunnigham LD et al. The prognostic value of CEA, b-HCG, AFP, CA125, CA19-9 and cERB2 immunohistochemistry in advanced colorectal cancer. Ann Oncol 1995; 6: 581-587.
13. Behbehani AI, Al Sayer H, Farghaly M et al. Prognostic significance of CEA and CA19-9 in colorectal cancer in Kuwait. Int J Biol Markers 2000; 15: 51-55.
14. Morales-Gutierrez C, Vegh I, Colina F et al. Survival of patients with colorectal carcinoma: possible prognostic value of tissue carbohydrate antigen 19-9 determination. Cancer 1999; 86: 1675-1681.
15. Nakayama T, Watanaba M, Teramoto T et al. CA19-9 as a predictor of recurrence in patients with colorectal cancer. J Surg Oncol 1997; 66:238-243.
16. Halubec L Jr, Topolcan O, Pikner R et al. The significance of CEA, CA19-9 and CA72-4 in the detection of colorectal carcinoma recurrence. Anticancer Res 2000; 20: 5237-5441.
17. Brown RW, Campagna LB, Dunn JK et al. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site. Am J Clin Path 1997; 107: 12-19.
18. Alvarez JA, Marin J, Jover JM et al. Sensitivity of monoclonal antibodies to carcinoembryonic tissue polypeptide antigen, alfa-fetoprotein, carbohydrate antigen 50 and CA19-9 in the diagnosis of colorectal adenocarcinoma. Dis Colon Rectum 1995; 38: 535-542.
19. Tucci GF, Grande M, Stopper I et al. Tissue expression of carbohydrate antigen CA19-9 in adenomatous lesions of the colorectum. Clin Ital 1999; 51: 165-172.
20. Gebaner G, Muller-Ruchholtz W. Carcinoembryonic antigen and CA19-9: implications of quantitative marker measurement in tissues for prognosis of colorectal cancer. Cancer Detect Prev 2001; 25: 344-351.
21. Lorenzi M, Vindigni C, Minacci C et al. Histopathological and prognostic evaluation at immunohistochemical findings in colorectal cancer. Int J Biol Markers 1997; 12: 68-74.
22. Seregni E, Ferrari L, Martinelli A et al. Diagnostic and prognostic tumor markers in gastrointestinal tract. Semin Surg Oncol 2001; 20: 147-166.
23. Duraker N, Celik A. The prognostic significance of preoperative serum CA19-9 in patients with resectable gastric carcinoma: comparison with CEA. J Surg Oncol 2001; 76:226-271.